Company news

Vistagen Therapeutics, Inc. news in 2025

Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

December 17, 2025

Vistagen Appoints Nick Tressler as Chief Financial Officer

December 1, 2025

Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

November 26, 2025

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

November 13, 2025

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

November 10, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

November 5, 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

November 3, 2025

Vistagen Appoints Paul Edick to its Board of Directors

October 29, 2025

Vistagen to Present at The Menopause Society 2025 Annual Meeting

October 16, 2025

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 9, 2025

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

August 7, 2025

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

July 31, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

July 24, 2025

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15, 2025

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

June 25, 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17, 2025

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

June 2, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

March 19, 2025

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

March 4, 2025

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

February 20, 2025

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

February 12, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

February 4, 2025

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

January 13, 2025

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

January 9, 2025

Calls in 2025

Decks in 2025